Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat
Laura E. Clemens(University of Tübingen), Huu Phuc Nguyen(University of Tübingen), Tanja T. Wlodkowski(University of Tübingen), Andreas Weiss(IRBM Science Park), Thierry Bordet, Rebecca M. Pruss(OZ Biosciences (France)), Libo Yu-Taeger(University of Tübingen), Jonasz Jeremiasz Weber(University Hospitals of the Ruhr-University of Bochum), Magali Michaud(OZ Biosciences (France)), Schamim H. Eckert(Goethe University Frankfurt), Carsten Calaminus(Siemens (Germany)), Gunter P. Eckert(Goethe University Frankfurt), Janett Gaca(Goethe University Frankfurt), Janine Magg(Bernstein Center for Computational Neuroscience Tübingen), Erik Jansson(University of Tübingen), Olaf Rieß(STZ eyetrial), Bernd J. Pichler(Siemens (Germany))
Cited by 42
Related Papers
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients
|Journal of Clinical Investigation|2015|270
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
|Cancer Discovery|2022|134
Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3)
|Human Molecular Genetics|2012|78
From Pathways to Targets: Understanding the Mechanisms behind Polyglutamine Disease
|BioMed Research International|2014|70
Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy
|Radiotherapy and Oncology|2020|57